 LEXINGTON, MA ACCESSWIRE April 7, 2020 Keros Therapeutics, Inc. Keros KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a high unmet medical need, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of 16.00 per share, for gross proceeds of 96.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Keros. All of the shares of common stock are being offered by Keros. 